MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications

Vaccine

Volumn 25, Issue 20, 2007, Pages 3955-3961

  Baldo, V ^a   Baldovin, T ^a   Floreani, A ^a   Carraro, A M ^a   Trivello, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adjuvant; High risk adults; Influenza vaccines

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; SUBUNIT VACCINE;

ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION COMPLICATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; ITALY; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SKIN INDURATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; RISK FACTORS; SQUALENE; VACCINES, SUBUNIT;

EID: 34247215969     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.045     Document Type: Article

References (23)

1. World Health Organization. Influenza. Fact sheet 211, March 2003. Available at http://www.who.int/mediacentre/factsheets/2003/fs211/en/ (accessed January 2007).
2. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2005;80:277-88.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 (2004) 1333-1340
4. Advisory Committee on Immunization Practices, Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 55 (2006) 1-42
5. Italian Ministry of Health. Influenza Vaccination Coverage. July 2006. Available at http://www.ministerosalute.it/promozione/malattie/documenti/ConfrontiAggiornati.pdf (accessed January 2007).
6. Italian Ministry of Health. Prevention and control of influenza: recommendations for the 2005-2006 season. August 2005. Available at http://www.ministerosalute.it/imgs/C_17_normativa_566_allegato.pdf (accessed January 2007).
7. Kroneman M., van Essen G.A., and Paget W.J. Influenza vaccination coverage and reasons to refrain among high-risk persons in four European countries. Vaccine 24 (2006) 622-628
8. Baldo V., Menegon T., Bonello C., Floreani A., and Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 (2001) 3472-3475
9. Squarcione S., Sgricia S., Biasio L.R., and Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21 (2003) 1268-1274
10. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2005-2006 influenza season. Wkly Epidemiol Rec 80 (2005) 74-75
11. Menegon T., Baldo V., Bonello C., Costa D.D., Di Tommaso A., and Trivello R. Influenza vaccines. antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 15 (1999) 573-576
12. Goodwin K., Viboud C., and Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24 (2006) 1159-1169
13. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96 12 March 1997. Available at www.emea.eu.int (accessed January 2007).
14. Beyer W.E., Palache A.M., Luchters G., Nauta J., and Osterhaus A.D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 103 (2004) 125-132
15. Potter C.W. A history of influenza. J Appl Microbiol 91 (2001) 572-579
16. Beyer W.E., de Bruijn I.A., Palache A.M., Westendorp R.G., and Osterhaus A.D. Protection against influenza after annually repeated vaccination. A meta-analysis of serologic and field studies. Arch Intern Med 159 (1999) 182-188
17. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., and Miller M.A. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165 (2005) 265-272
18. Del Giudice G., Hilbert A.K., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24 (2006) 3063-3065
19. Beyer W.E.P., Palache A.M., Sprenger M.J.W., Hendriksen E., Tukker J.J., Darioli R., et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 14 (1996) 1331-1339
20. Hak E., Buskens E., van Essen G.A., de Bakker D.H., Grobbee D.E., Tacken M.A., et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 165 (2005) 274-280
21. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 (1999) 3094-3101
22. Frey S., Poland G., Percell S., and Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21 (2003) 4234-4237
23. Iob A., Brianti G., Zamparo E., and Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133 (2005) 687-693